Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,773 shares of the pharmaceutical company’s stock after acquiring an additional 39 shares during the period. Integrated Investment Consultants LLC’s holdings in Vertex Pharmaceuticals were worth $7,963,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at about $25,000. Highline Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $27,000. Dunhill Financial LLC raised its position in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC purchased a new position in Vertex Pharmaceuticals in the third quarter worth approximately $33,000. Finally, Truvestments Capital LLC purchased a new stake in Vertex Pharmaceuticals in the third quarter valued at $35,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Up 1.2 %

VRTX opened at $422.00 on Friday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The business’s 50 day moving average is $442.83 and its two-hundred day moving average is $466.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the subject of a number of research analyst reports. Morgan Stanley increased their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. BMO Capital Markets reduced their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research note on Friday, December 20th. Scotiabank upped their price objective on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, November 5th. Finally, Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $500.00 to $550.00 in a research report on Monday, December 9th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.